FTC Rebukes Supernus Efforts To Block Sales Of Injector Pen For Use With Generic Apokyn

Agency refutes Supernus’ defense that Sage’s generic drug cartridges are ‘free-riding’ on the supply of the injector pen for its branded product. Company’s alleged exclusionary contract with pen distributor and pressure on specialty pharmacies not to provide the generic involve important antitrust issues, FTC tells court.

FTC building statue — FTC intervenes in antitrust complaint over Parkinson's disease treatment • Source: Shutterstock

The US Federal Trade Commission intervened in Sage Chemical, Inc.’s antitrust suit against Supernus Pharmaceuticals, Inc., criticizing Supernus’ alleged strategies to block entry of a generic version of its Apokyn (apomorphine hydrochloride injection) by leveraging control over the Apokyn pen injector and rebutting Supernus’s defense.

Sage is in an unusual position as it must have access to the auto injector pen used to deliver Apokyn...